United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2003_register
executive
2010-09-23
article
Prospective Grant of Exclusive License: Zenapax (Humanized Antibody Against the IL-2 Receptor Alpha Chain) as a Novel Treatment for Multiple Sclerosis
Notices
D09002ee1bdeaf5fe
D09002ee1bdeaf694
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
National Institutes of Health
originator
org
United States Government Agency or Subagency
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. provisional patent application 60/393,021 (DHHS ref. no. E-143-2002/0- US-01) filed June 28, 2002, international PCT application PCT/US02/ 38290 (DHHS ref. no. E-143-2002/0-PCT-02), international PCT application PCT/US03/20428 (DHHS ref. no. E-143-2002/0-PCT-04), and United States Patent Application Serial No. 10/607,598 (DHHS ref. no. E-143-2002/0-US-03), all entitled, ``Zenapax (Humanized Antibody Against the IL-2 Receptor Alpha Chain) As A Novel Treatment for Multiple Sclerosis,'' and all corresponding foreign patent applications to Protein Design Laboratories, of Fremont, California. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory will be worldwide. The field of use may be limited to the treatment of multiple sclerosis using monoclonal antibodies against the interleukin-2 receptor.
68 FR 70826
https://www.govinfo.gov/app/details/FR-2003-12-19/03-31326
03-31326
fr19de03-92
4140-01-P
https://www.govinfo.gov/app/details/FR-2003-12-19/03-31326
https://www.govinfo.gov/content/pkg/FR-2003-12-19/html/03-31326.htm
https://www.govinfo.gov/content/pkg/FR-2003-12-19/pdf/03-31326.pdf
2 p.
70826
70827
68 FR 70826
Prospective Grant of Exclusive License: Zenapax (Humanized Antibody Against the IL-2 Receptor Alpha Chain) as a Novel Treatment for Multiple Sclerosis; Federal Register Vol. 68, Issue
NOTICE
03-31326
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
2004-02-17
4140-01-P
03-31326
Notice.
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. provisional patent application 60/393,021 (DHHS ref. no. E-143-2002/0- US-01) filed June 28, 2002, international PCT application PCT/US02/ 38290 (DHHS ref. no. E-143-2002/0-PCT-02), international PCT application PCT/US03/20428 (DHHS ref. no. E-143-2002/0-PCT-04), and United States Patent Application Serial No. 10/607,598 (DHHS ref. no. E-143-2002/0-US-03), all entitled, ``Zenapax (Humanized Antibody Against the IL-2 Receptor Alpha Chain) As A Novel Treatment for Multiple Sclerosis,'' and all corresponding foreign patent applications to Protein Design Laboratories, of Fremont, California. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory will be worldwide. The field of use may be limited to the treatment of multiple sclerosis using monoclonal antibodies against the interleukin-2 receptor.
Only written comments and/or license applications which are received by the National Institutes of Health on or before February 17, 2004 will be considered.
Patent licenses; non-exclusive, exclusive, or partially exclusive:
Protein Design Laboratories,
joycec@mail.nih.gov
Federal Register
Vol. 68, no. 244
Office of the Federal Register, National Archives and Records Administration
2003-12-19
continuing
daily
deposited
born digital
317 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2003-12-19
P0b002ee1809d7402
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr19de03
https://www.govinfo.gov/app/details/FR-2003-12-19
https://www.govinfo.gov/content/pkg/FR-2003-12-19/pdf/FR-2003-12-19.pdf
https://www.govinfo.gov/content/pkg/FR-2003-12-19/xml/FR-2003-12-19.xml
fdlp
70689
70994
DGPO
2010-09-23
2023-05-04
FR-2003-12-19
machine generated
eng
FR
FR-2003-12-19
68
244